Zevra Therapeutics, Inc. (ZVRA)
Summary
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability.
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market
Zevra Therapeutics reported Q3 FY25 revenues of $26.1M, up 605% YoY, driven by MIPLYFFA, and is nearing profitability. ZVRA's valuation appears deeply discounted, with significant upside from EU expansion, pipeline assets Celiprolol and KP-1077, and a strong $200M cash position. FY26 is projected as the first year of true profitability, with analyst EPS estimates between $0.29 and $1.07 and revenue growth driven by MIPLYFFA.
Zevra Therapeutics, Inc. (ZVRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Zevra Therapeutics, Inc. ever had a stock split?
Zevra Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Neil F. McFarlane CEO | NASDAQ (NGS) Exchange | 488445206 CUSIP |
| US Country | 59 Employees | - Last Dividend | 28 Dec 2020 Last Split | - IPO Date |
Overview
Zevra Therapeutics, Inc., initially known as KemPharm, Inc., rebranded itself in February 2023 and has established its operations in Celebration, Florida, since its inception in 2006. The company is at the forefront of discovering and developing a range of proprietary prodrugs aimed at treating severe medical conditions in the United States. Leveraging its Ligand Activated Therapy platform, Zevra Therapeutics strives to innovate in the pharmaceutical landscape by advancing its lead candidates and a diverse portfolio of drugs through clinical trials, targeting various disorders. Through strategic collaborations and licensing agreements with entities like Commave Therapeutics SA and Acer and Relief Therapeutics, Inc., Zevra Therapeutics is expanding its footprint in the development, manufacture, and commercialization of novel prodrugs.
Products and Services
- KP1077
A leading product candidate developed for the treatment of sleep disorders, KP1077 is undergoing rigorous testing. KP1077IH is in a Phase 2 clinical trial targeting idiopathic hypersomnia, a sleep disorder causing excessive daytime drowsiness. Concurrently, KP1077N is navigating through a Phase 1/2 clinical trial aimed at managing narcolepsy, a condition characterized by sudden sleep attacks.
- Celiprolol
A prodrug candidate, Celiprolol, is under Phase 1/2 clinical assessment for treating vascular Ehlers Danlos syndrome, a rare genetic disorder affecting the body's connective tissue. This pioneering treatment approach underscores Zevra's commitment to addressing complex, rare diseases through innovative therapies.
- AZSTARYS
This once-daily treatment is designed for patients aged six years and older struggling with attention deficit hyperactivity disorder (ADHD). AZSTARYS represents Zevra Therapeutics' strides towards providing relief and support to individuals and families affected by ADHD through advanced pharmaceutical solutions.
- OLPRUVA
Targeting urea cycle disorders, OLPRUVA is part of Zevra Therapeutics' portfolio aimed at treating metabolic diseases. By focusing on such disorders, the company illustrates its dedication to tackling less common but impactful health conditions with groundbreaking drug developments.
- Arimoclomol
Designed to combat niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder, Arimoclomol is a testament to Zevra Therapeutics' commitment to addressing neurodegenerative diseases through advanced therapeutic strategies. This initiative highlights the company's dedication to innovation and care for individuals battling severe, life-altering conditions.
